Summer’s King of Wines!

Happy summer! For this column, I wanted to take on a very difficult task. Barolo has been called “the King of Wines” for a very long time, and they don’t come cheap. My goal was to find three good Barolos at a reasonable price. I hosted a tasting of six Barolos, all less than $45 retail, and all with reviews of 90 points or more. Six advertising colleagues, all who like wine, but none who are aficionados, did the judging.

Ascheri 2012 Barolo

A blend of premium Zinfandel, Petite Sirah, Cabernet Sauvignon, Carignane, Alicante Bouschet, and Viognier that’s lively and delicious with ripe blueberry, raspberry, and blackberry fruits. The wine received a review of 91 points from The Wine SpectatorThe wine retails for $30.

Damilano 2013

A 93 rating from wine expert Robert Parker, with an amazing nose and notes of tobacco. It has a soft finish, which is the factor that differentiated it from the remaining wines we tasted.

The wine retails for $42.

Bruna Grimaldi Barolo Bricco Ambrogio 2013

The Wine Enthusiast gave this wine a 93. Truly my favorite of the group. This wine has an amazing bouquet, a beautiful red color, and intense flavors including lots of fruit and a hint of pepper. The finish is fresh and pleasant. I will likely buy a case. The wine retails for $40.

Pro Tip: One of the things that raise the price of the wine is the finish. Many reds have a somewhat unpleasant aftertaste. You can save a bundle by selecting a nice red with a great nose and a smooth and pleasant flavor, but which is marred by a poor finish. Serve it with food…and the finish is no longer an issue.

Ads

You May Also Like

PM360 2018 Trailblazer Awards Women’s Health Brand Champion Tonya Conklin

Tonya Conklin, Associate Director, Marketing, AbbVie Endometriosis does not get the attention it deserves, ...

The Challenge of Innovation

“Innovation is hard,” Nolan Bushnell, an electrical engineer who founded companies including Atari and ...

Industry Briefs October 2018

Hospitals Plan to Produce Own Generics As the FDA struggles to find solutions to ...